Clinical Trial Update: A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A completed Phase 2 clinical trial evaluating Motexafin Gadolinium (Xcytrin) for relapsed or refractory multiple myeloma, sponsored by Pharmacyclics LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Xcytrin (motexafin gadolinium)

Snippet

Sponsor: Pharmacyclics LLC. | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED